Here are some news/notes on a day in MedCity, Minnesota:
Uroplasty Inc.’s stock price jumped 4.6 percent Tuesday after the company announced positive results from study of its incontinence treatment, according to the Minneapolis-St. Paul Business Journal. The movement comes after the Minnetonka-based medical device developer reported favorable results from a large study to be published in the April 2010 Journal of Urology.
A Minnetonka startup believes that it may have an answer to Alzheimer’s, according to Finance & Commerce. Medisyn Technologies, in collaboration with the Mount Sinai School of Medicine in New York, has identified eight chemical compounds that may eventually reduce the buildup of an abnormal protein that is found in the brain of all Alzheimer’s patients.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Mayo Clinic said Tuesday that the Michael J. Fox Foundation awarded a $500,000 grant to a neuroscientist at its campus in Florida. The researcher, Matthew Farrer, studies how a gene, known as LRRK2, functions normally within brain nerve cells (neurons), and also how it can go awry when mutated. Dr. Farrer was part of the original team who discovered the link between LRRK2 and Parkinson’s disease in 2004.
